Drug Profile

ARV 806

Alternative Names: ARV-806; ARV-806 KRAS protein degraders - Arvinas; PROTAC KRAS G12D degrader; PROTAC^®Y

Latest Information Update: 07 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arvinas
Class Antineoplastics; Small molecules
Mechanism of Action KRAS protein degraders; Proteolysis

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

29 May 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT07023731)
02 May 2025 Arvinas files an IND application with the US FDA for Solid tumours prior to May 2025
02 May 2025 US FDA approves IND application for ARV 806 in Solid tumours prior to May 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com